YAP1 and non-small cell lung carcinoma: For alectinib, the mechanism has been attributed to transcriptional regulation by the activation of Yes-associated protein1 (YAP1; target for therapy: the YAP-TEAD pathway) in patient-derived NSCLC cell lines10,13.